eXoZymes Share Price Today

eXoZymes CEO to discuss commercialization and milestones in fireside chat

eXoZymes CEO Michael Heltzen joins Water Tower Research for a fireside chat on October 22, 2026. Discussion focuses on commercializing NCT, a rare molecule for nutraceutical and pharma markets. Company highlights asset-light model, relying on partners like Curia for scale-up rather than internal facilities. Topics include manufacturing economics, NCTx subsidiary revenue potential, and rare cannabinoid applications.

eXoZymes Q2FY26 Results: Net loss widens to $2.88M, raises $6M

Net loss widened to $2.88M in Q2 2026 as operating expenses rose to $2.95M from $2.55M YoY. Raised $6M via underwritten public offering in June to strengthen capital position. Secured $2M NIH SBIR grant for preclinical development of cannabinoid analogs. Cash balance of $5.65M expected to fund operations through end of 2026. Lead NCT program showed 10-fold productivity increase since pilot scale.

eXoZymes NCT process sees 10x productivity gain, 100x cost drop

eXoZymes Inc. reported a 10-fold productivity increase in its NCT manufacturing process, driven by a 67% higher output per liter and an 80% reduction in reaction time. Estimated manufacturing costs fell by more than 100x compared to the initial process version, supporting the company's move toward technology transfer and commercial scale.

eXoZymes Q2 Results: Update call scheduled for August 20

eXoZymes Inc. scheduled a Q2 2026 update call for August 20, 2026. CEO Michael Heltzen will discuss financial results and business initiatives. The company focuses on AI-enhanced enzymes for nutraceuticals and medicines.

eXoZymes awarded $2M NIH grant to advance cannabinoid analogs

eXoZymes Inc. received a $2,028,518 Phase IIB SBIR grant from the NIH to advance cannabinoid analogs for drug discovery. The two-year project, beginning July 1, 2026, aims to develop proprietary enzyme-based manufacturing technologies. This award increases the company's total non-dilutive funding to $19.7 million.

eXoZymes closes $5.95 million public offering to fund development

eXoZymes Inc. closed a public offering of 330,575 units, comprising common stock and warrants, with gross proceeds of approximately $5.95 million. The shares were priced at $8.99 and warrants at $0.02, with warrants exercisable at $11.24 after one year. Proceeds will fund NCT development, R&D, and working capital.